title: Chemoradiotherapy for gastrointestinal cancers.
abstract: New combinations of chemotherapy with radiotherapy for gastrointestinal cancers are showing evidence that improved outcomes may result from toxicity profiles associated with "targeted" systemic radiosensitizing agents. These new agents are also clinically attractive owing to such factors as oral bioavailability and patient dosing schedules, making them practical and convenient compared with older intravenous administration requirements. Several new classes of radiosensitizing agents are discussed here and underscore aspects of molecular activation in tumors rather than normal tissues because of differences in pathways of metabolism or based on the process of tumor-associated angiogenesis.
authors.affiliation: Department of Radiation Oncology, University of Virginia, PO Box 800383, Charlottesville, VA 22908, USA. tar4d@virginia.edu
authors.forename: Tyvin A
authors.initials: TA
authors.lastname: Rich
authors.forename: Christopher
authors.initials: C
authors.lastname: Crane
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Lawson
authors.forename: Jerome
authors.initials: J
authors.lastname: Landry
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D011878:Radiotherapy / Q000379:methods
chemical_list: D000970:Antineoplastic Agents